团队长期从事泌尿外科临床和科研工作，一直关注膀胱癌发病机制与诊疗技术的研究。课题组发表相关 SCI 学术论文 40余篇，申请专利3项，授权专利2项。申请人完成国家自然科学基金面上项目3项。另有科技部子课题1项，国家临床重点专科建设项目负责人，国家自然科学基金面上项目1项（在研）。所在单位为同济大学附属的最大的三甲综合医院，同济大学癌症中心的依托单位，拥有国家临床重点专科6个，上海市工程中心2个，上海市技术创新中心1个，上海市技术服务中心1个，上海市医学研究中心2个，“一带一路”国际联合实验室1个。所在泌尿外科承担国家临床重点专科建设项目，主要科研方向之一为膀胱癌基础研究，近5年发表相关论文60余篇。团队拥有专业技术人员多名，熟悉分子生物学相关实验技术及实验动物的管理及相关技术，有熟练的材料学操作技能，掌握纳米材料特征、合成方法及操作流程，为课题的顺利实施提供了技术保障。

近五年科研课题

1. Yilin Yan#, Zhengnan Huang#, Jinming Cai, Pengfei Tang, Fang Zhang*, Mingyue Tan*, Bing Shen*.Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer. Aging 2021, Vol. 13, No. 2.2780-2802.

2. Zhengnan Huang# ,Yilin Yan#, Pengfei Tang, Jinming Cai, Xiangqian Cao, Zeyi Wang, Fang Zhang*, Bing Shen*. TEAD4 as a Prognostic Marker Promotes Cell Migration and Invasion of Urinary Bladder Cancer via EMT. OncoTargets and Therapy. 2021:14 937–949.

3. Shenyi Wang#, Jinming Cai#, Si Zhang, Mingwei Dong, Li Zhang,Yingying Xu*, Bing Shen*,She Chen*.Loss of polarity protein Par3, via transcription factor Snail,promotes bladder cancer metastasis. Cancer Science. 2021;00:1–17.

4. Zhengnan Huang #, Yilin Yan #, Zhen Zhu #, Jiakuan Liu, Xiao He, Sumiya Dalangood, Meiqian Li, Mingyue Tan, Jinming Cai, Pengfei Tang, Ruimin Huang, Bing Shen*, Jun Yan*. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling. Cell Death Dis. 2021 May 25;12(6):537. doi: 10.1038/s41419-021-03819-0.

5. Yilin Yan#, Jinming Cai#, Zhengnan Huang , Xiangqian Cao, Pengfei Tang , Zeyi Wang , Fang Zhang*, Shujie Xia* and Bing Shen*.A Novel Ferroptosis-related Prognostic Signature Reveals Macrophage Infiltration and EMT Status in Bladder Cancer. Front Cell Dev Biol. 2021 Aug 20;9:712230. doi: 10.3389/fcell.2021.712230. eCollection 2021.

6. Zhengnan Huang#; Jiakuan Liu#; Jiale Yang; Yilin Yan; Chenkai Yang; Xiao He; Ruimin Huang; Mingyue Tan; Denglong Wu*, Jun Yan* and Bing Shen*. PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7. Frontiers in Cell and Developmental Biology, 2021, 9(712230)

7. Yilin Yan#, Xiangqian Cao#, Zeyi Wang, Zhengnan Huang , Jinming Cai , Pengfei Tang , Chenkai Yang , Fang Zhang*, Shujie Xia* and Bing Shen*. Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer. Front Mol Biosci. 2022 Apr 26;9:815290. doi: 10.3389/fmolb.2022.815290. eCollection 2022.

8. Zhengnan Huang#, Yilin Yan#, Tengjiao Wang#, Zeyi Wang，Jinming Cai, Xiangqian Cao, Chenkai Yang, Fang Zhang*, Gang Wu* and Bing Shen*.Identifcation of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer. Journal of Translational Medicine (2022) 20:315 https://doi.org/10.1186/s12967-022-03509-1.

9. Jinming Cai#, Zhiwen Xie#, Yilin Yan , Zhengnan Huang , Pengfei Tang, Xiangqian Cao, Zeyi Wang, Chenkai Yang, Mingyue Tan*, Fang Zhang* and Bing Shen*. Establishment of an optimized orthotopic bladder cancer model in mice. BMC Urology (2022)22:142. https://doi.org/10.1186/s12894-022-01093-6.

10. Jinming Cai#, Haoran Xie#, Yilin Yan, Zhengnan Huang, Pengfei Tang, Xiangqian Cao, Zeyi Wang, Chenkai Yang, Jiling Wen*, Mingyue Tan*, Fang Zhang* and Bing Shen*. A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer. Frontiers in Genetics, 04 January 2023, DOI 10.3389/fgene.2022.1082691.

11. Zeyi Wang#，Zhengnan Huang# , Xiangqian Cao#, Fang Zhang , Jinming Cai, Pengfei Tang, Chenkai Yang, Shengzhou Li, Dong Yu, Yilin Yan, Bing Shen*. A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer. BMC Urol, 2023 Jan 28;23(1):10. doi: 10.1186/s12894-023-01175-z.

12. Jingming Zhuang#, Jiahang Mo#, Zhengnan Huang, Yilin Yan, Zeyi Wang, Xiangqian Cao, Chenkai Yang, Bing Shen* and Fang Zhang*. Mechanisms of Xiaozheng decoction for anti-bladder cancer efects via afecting the GSK3β/β-catenin signaling pathways: a network pharmacology-directed experimental investigation. Chinese Medicine, 2023 18:104: doi.org/10.1186/s13020-023-00818-5

13. Xiangqian Cao#, Chenkai Yang#, XiaodongZhu#, Mengxin Zhao, Yilin Yan, Zhengnan Huang, Jinming Cai, Jingming Zhuang,Shengzhou Li, Wei Li*, Bing Shen*. Synergistic enhancement of chemotherapy forbladder cancer by photothermal dual-sensitive nanosystem with goldnanoparticles and PNIPAM. Chinese Chemical Letters. 2024, 35(8), 109199.

14. Gu, Z., Zou, L., Pan, X., Yu, Y., Liu,Y., Zhang, Z., Liu, J., Mao, S., Zhang, J., Guo, C., Li, W., Geng, J., Zhang,W., Yao, X., & Shen, B. (2024). The role and mechanism of NAT10-mediatedac4C modification in tumor development and progression. MedComm, 5(12), e70026.

15. Yang, C., Pan, X., Zhao, W., Qiu, Z.,He, L., Wu, C., ... & Li, W. (2025). Intratumoral photo-controlled antigensburst release for synergistic immunotherapy by bio-membrane and organicmembrane coated dual-functional nanoparticles. Chinese Chemical Letters, 36(9),110740.

16. Yan, Y., Huang, Z., Zhu, Z., Wang, Y.,Cao, X., Yang, C., Jiang, J., Xia, S., & Shen, B. (2024). IMP2 driveschemoresistance by repressing cisplatin-induced apoptosis and ferroptosis viaactivation of IPO4 and SLC7A11 under hypoxia in bladder cancer. Cancer cellinternational, 24(1), 386.

17. Huang, L., Lv, W., Huang, Q., Zhang,H., Jin, S., Chen, T., & Shen, B. (2024). Medical equipment effectivenessevaluation model based on cone-constrained DEA and attention-based bi-LSTM.Scientific reports, 14(1), 9324.

18. Li, S., Chen, Y., Cao, X., Yang, C.,Li, W., & Shen, B. (2024). The application of nanotechnology in kidneytransplantation. Nanomedicine (London, England), 19(5), 413–429.

19. Huang, L., Lv, W., Huang, Q., Zhang,H., Jin, S., Chen, T., & Shen, B. (2024). Transforming medical equipmentmanagement in digital public health: a decision-making model for medicalequipment replacement. Frontiers in medicine, 10, 1239795.

20. Yao, R., Ai, B., Wang, Z., Shen, B.,Xue, G., & Yu, D. (2024). Uncovering Microbial Composition of the TissueMicroenvironment in Bladder Cancer using RNA Sequencing Data. Journal ofCancer, 15(8), 2431–2441.

21. Huang, Z., Wang, Z., Xu, C., Yan, Y.,Cao, X., Zhang, F., & Shen, B. (2024). FGL2 as a predictive biomarker forprognosis and immunotherapy in bladder cancer. International journal of medicalsciences, 21(8), 1447–1460.

22. Zhang, H., Li, Z.,Huang, Q., Huang, L., Huang, Y., Wang, W., & Shen, B. (2025). CS-SwinGAN: Aswin-transformer-based generative adversarial network with compressed sensingpre-enhancement for multi-coil MRI reconstruction. Biomedical SignalProcessing and Control, 110, 108120.

23. Liu W, Kadier A, Tang C, et al.Comparison of combined MRI-TRUS fusion targeted and systematic biopsy vssystematic biopsy alone for the detection of prostate cancer in the Chinesebiopsy-naïve patients: a prospective, single-center trial[J]. InternationalJournal of Surgery, 2026, 112(3): 6677-6685.

24. Yu Wang, Zhongqi Cui, Yang Wang,Chunhui Wang, Yue Zhang Nan Huang, Xinda Yang, Fenyong Sun, Sufeng Qiang, ShuoShi, Bing Shen*. ISRIB-loaded nanoplatform disrupts cellular homeostasis bydepleting glutathione and inhibiting stress granules formation to driveimmunosuppressive reprogramming[J]. Chemical Engineering Journal, 2025, 523(-):168568.

25. Mao S, Guo Y, Dong C, Wang D, Wang X,Weng L, Yang Y, Li Y, Niu T, Wu Q, Zheng Z, Shan Z, Tan X, Gao Y, Jin J, WangP, Ge X, Shen B, Yao X, Fang L. Loss of cyclin C drives resistance toanti-TIGIT therapy by upregulating CD155-mediated immune evasion. Drug ResistUpdat. 2026 Jan;84:101318.

26. Yang Wang, Huaxing Li, Xiangqian Cao,Weiguang Zhao, Hongquan Gou, Chenkai Yang, Haoyuan Wang, Jie Deng, Wen Chen,Haipeng Qi, Dongsheng Mao, Xiaoli Zhu, Bing Shen*. ISRIB-loaded nanoplatformdisrupts cellular homeostasis by depleting glutathione and inhibiting stressgranules formation to drive immunosuppressive reprogramming[J]. ChemicalEngineering Journal, 2025, 523(-): 168311.

27. Luo W, Chen Y, Shen D, Zhang Y, ZhangW, Xu T, Chen H, Cao X, Yan Y, Yang B, Li W, Shen B. Emotional stress: aprominent factor positively related to the onset and recurrence of bladdercancer as revealed by NHANES and a Chinese database. Ann Med. 2025 Dec;57(1):2549525.

28. Dongsheng Mao, Hongquan Gou, Wen Chen,Rui Zhu, Fanping Zhang, Wentao Zhang, Yuanyuan Zhang, Xiaozhi Huang, Min Li,Wenxing Li, Bing Shen, Xiaoli Zhu. Enzymatic DNA orthogonal chemistry formulti-cancer diagnosis[J]. Chem, 2025, 11(12).

29. Yang, Y., Guo, Y., Mao, S., Dong, C.,Yu, Z., Yao, X., & Shen, B. (2025). CBS promotes tumor immune evasion byreducing MHC-I stability. Genes & Diseases, 101782.

30. Xinda Yang, Nan Huang, Mingyang Li,Xiaoli Zhu, Chunhui Wang, Yue Zhang, Chuansheng Xu, Niantong Yang, Sirui Chen,Yuheng Pan, Bing Shen & Shuo Shi. A new oxaliplatin(IV) prodrug inducingferroptosis through a triple-pathway mechanism and activating anti-cancerimmunity. Sci. China Chem. 68, 4297–4310 (2025)

31. Huang Q, Huang L, Zhang H, Huang Y,Wang W, Cheng Y and Shen B (2025) Design method of magnetic resonance biplanargradient coil based on target field method and stream function. Front. Phys.13:1579043.

32. Li, S., Duan, F., Qiu, Z., Nan, Z.,Cao, X., Yang, C., Li, W., & Shen, B. (2025). Polymer-Conjugated SOD-Pt⁰ Micelles Enhance ROS Cascade Scavenging to AlleviateIschemia-Reperfusion Injury During Kidney Transplantation. Advanced healthcarematerials, 14(16), e2500696.

33. Dong, Z., She, X., Ma, J., Chen, Q.,Gao, Y., Chen, R., Qin, H., Shen, B., & Gao, H. (2025). The E3 LigaseNEDD4L Prevents Colorectal Cancer Liver Metastasis via Degradation of PRMT5 toInhibit the AKT/mTOR Signaling Pathway. Advanced science (Weinheim,Baden-Wurttemberg, Germany), 12(26), e2504704.

34. Zhuang, J., Wang, Y., Wu, X., Peng, Z.,Huang, Z., Zhao, C., & Shen, B. (2025). SIGMAR1 screened by a GPCR-relatedclassifier regulates endoplasmic reticulum stress in bladder cancer. Journal oftranslational medicine, 23(1), 417.

35. Cao, X., Yan, Y., Zhu, X., Huang, Z.,Yang, C., Zhao, W., ... & Shen, B. (2025). Application ofaggregation-induced emission (AIE) in the urinary system disease. BiofunctionalMaterials, 3(1), 1-28.

36. Mao, D., Tang, X., Zhang, R., Hu, S.,Gou, H., Zhang, P., Li, W., Pan, Q., Shen, B., & Zhu, X. (2025).Multichrome encoding-based multiplexed, spatially resolved imaging revealssingle-cell RNA epigenetic modifications heterogeneity. Nature communications,16(1), 958.

37. Nan, Z., Zhao, W., Li, S., Yue, C., Cao, X., Yang, C., Yan, Y., Sun,F., & Shen, B. (2026). Unequal Progress in Early-Onset Bladder CancerControl: Global Trends, Socioeconomic Disparities, and Policy Efficiency from1990 to 2021. Healthcare (Basel, Switzerland), 14(2),193.

38. Huang, Z., Cao, X., Yan, Y., Li, H.,Shen, B., & Wang, T. (2026). Integrative analysis of the PSMA familyidentifies PSMA6 as an adverse prognostic biomarker promoting bladder cancercell proliferation. International journal of medical sciences, 23(3),986–1001.

39. Cai, J., Jiao, C., Xu, Y., Zhang, F.,Zhang, L., Chen, S., & Shen, B. (2026). Polarity protein Par3 deficiencypromotes metastasis of bladder cancer via interaction of Ppp1r12c. Biologydirect, 21(1), 22.

40. Zou, J., Meng, G., Huang, Y., Huo, J.,Yuan, H., Ma, H., You, Z., Yan, X., Shen, B., Zhang, M., & Yang, Y. (2026).An intermediate-crystalline phase manganese nanoadjuvant potently activatescGAS-STING signaling and antitumor immunity via immunometabolism normalization.Biomaterials, 328, 123901.